Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 18, 2007

Vegenics Licenses Antibodies from CoGenesys

  • Vegenics licensed from CoGenesys exclusive, worldwide rights to human mAbs that target vascular endothelial growth factor-C (VEGF-C). VEGF-C is believed to play an important role in promoting the formation of new blood vessels and the maintenance of existing blood vessels.

    "Our partnership with Vegenics is a great example of our business model, in which multiple, early-stage partnering agreements will generate a continuing revenue stream to support our own internal development activities," says Mark Rampy, CBO of CoGenesys.

  • You’re all set! Thank you for subscribing to GEN Highlights.